Phathom Pharmaceuticals, Inc. Depreciation & Amortization

Depreciation & Amortization of PHAT for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending September 29, 2021 was $130 Thousand (a -0.76% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization increased by 22.64%
  • Annual Depreciation & Amortization for 2020 was $323 Thousand (a 3937.5% increase from previous year)
  • Twelve month Depreciation & Amortization ending September 29, 2021 was $492 Thousand (a 9.33% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization decreased by -43.25% year-over-year
Trailing Depreciation & Amortization for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$492 Thousand $450 Thousand $741 Thousand $867 Thousand
Visit stockrow.com/PHAT for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of Phathom Pharmaceuticals, Inc.

Most recent Depreciation & Amortizationof PHAT including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of Phathom Pharmaceuticals, Inc.

Phathom Pharmaceuticals, Inc. Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.13 $0.13 $0.13
2020 $0.11 $0.09 $0.42 $0.25 $0.32
2019 $0.17 $0.16 $0.08 $0.01
2018 $0.0

Business Profile of Phathom Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.